Royalty Pharma PLC (NAS:RPRX)
$ 26.6 0.31 (1.18%) Market Cap: 11.82 Bil Enterprise Value: 17.66 Bil PE Ratio: 10.43 PB Ratio: 1.73 GF Score: 79/100

Royalty Pharma PLC at Evercore ISI HealthCONx Virtual Conference Transcript

Dec 02, 2021 / 02:40PM GMT
Release Date Price: $38.88 (+0.28%)
Umer Raffat
Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research

Thank you, guys, for joining us. Pleasure to have the CEO and CFO of Royalty Pharma join us. There's a lot to talk about. But before we do, let me first turn it over to Pablo to kick things off and maybe share some opening comments.

Pablo Legorreta
Royalty Pharma plc - Founder, Chairman of the Board & CEO

Umer, thank you very much. And good morning to everyone. It is a pleasure to be here to discuss Royalty Pharma and share why we're so excited about the future of our business. For those of you not familiar with Royalty Pharma, we have been a pioneer and leader in the royalty market for over 20 years. The royalty market is growing rapidly as royalty funding in biopharma becomes more widely accepted and awareness grows. For context, there was around $5.4 billion of royalty transactions in 2020. And we think this is just a fraction of the total addressable market.

Our business model is unique in that it provides many of the best

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot